Iverjohn is a prescription medication containing the active ingredient ivermectin, designed to treat parasitic infections by targeting the nervous systems of parasites, leading to their paralysis and elimination. This antiparasitic agent is widely recognized for its efficacy in managing conditions such as strongyloidiasis and onchocerciasis, providing relief from symptoms and preventing complications associated with these infections. Proper usage under medical supervision ensures optimal therapeutic outcomes while minimizing risks.

Features

• Active ingredient: Ivermectin 3 mg or 6 mg tablets
• Mechanism: Binds to glutamate-gated chloride ion channels in invertebrate nerve and muscle cells
• Formulation: Oral tablets with high bioavailability
• Packaging: Blister packs of 4, 10, or 20 tablets
• Shelf life: 36 months from date of manufacture
• Manufacturer compliance: WHO Good Manufacturing Practices (GMP)

Benefits

• Effectively eliminates parasitic infections by causing paralysis and death of target parasites
• Reduces symptoms such as itching, skin lesions, and gastrointestinal distress
• Helps prevent long-term complications like blindness in cases of onchocerciasis
• Supports improved nutritional absorption and overall health by clearing intestinal parasites
• Convenient single or limited dosing regimen in many cases
• Contributes to public health efforts in endemic regions by reducing transmission

Common use

Iverjohn is primarily indicated for the treatment of parasitic infections including strongyloidiasis (caused by Strongyloides stercoralis) and onchocerciasis (river blindness, caused by Onchocerca volvulus). It may also be used off-label for other parasitic conditions as determined by a healthcare provider, such as scabies or certain types of filariasis, following appropriate diagnostic confirmation.

Dosage and direction

Dosage is based on body weight and the specific infection being treated. For strongyloidiasis, the typical dose is 200 mcg per kg of body weight orally as a single dose. For onchocerciasis, the usual dose is 150 mcg per kg orally as a single dose; retreatment may be required every 6 to 12 months until asymptomatic. Tablets should be taken on an empty stomach with a full glass of water to maximize absorption. Do not crush or chew tablets.

Precautions

• Use only under the supervision of a qualified healthcare professional.
• Inform your doctor of any liver or kidney conditions, as dosage adjustments may be necessary.
• Not recommended during pregnancy unless potential benefits outweigh risks.
• Breastfeeding should be avoided during treatment and for several days after the last dose.
• May cause dizziness or drowsiness; avoid driving or operating machinery until effects are known.
• Regular monitoring may be required for individuals with compromised immune systems.

Contraindications

• Hypersensitivity to ivermectin or any component of the formulation.
• Concurrent use with other agents that increase blood-brain barrier permeability (e.g., certain immunosuppressants).
• History of severe central nervous system disorders.
• Children weighing less than 15 kg, unless specifically advised by a physician.

Possible side effect

Common side effects may include dizziness, nausea, diarrhea, pruritus, rash, and transient elevation of liver enzymes. Less frequently, orthostatic hypotension, tachycardia, or visual disturbances may occur. In mass treatment programs for onchocerciasis, Mazzotti-type reactions (fever, rash, arthralgia, lymph node enlargement) are possible due to parasite death.

Drug interaction

Iverjohn may interact with drugs that inhibit CYP3A4 enzymes (e.g., ketoconazole, ritonavir), potentially increasing ivermectin plasma levels. Concurrent use with warfarin may alter anticoagulant effects. Use with caution alongside other central nervous system depressants. Always inform your healthcare provider of all medications, including over-the-counter products and supplements.

Missed dose

If a dose is missed, take it as soon as remembered unless it is almost time for the next dose. Do not double the dose to catch up. Follow your healthcare provider’s instructions regarding missed doses, especially in regimens requiring precise timing.

Overdose

Symptoms of overdose may include nausea, vomiting, diarrhea, dizziness, hypotension, and respiratory depression. In case of suspected overdose, seek immediate medical attention. Supportive care and symptomatic treatment are mainstays of management; there is no specific antidote.

Storage

Store at room temperature (15–30°C) in a dry place, protected from light and moisture. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging.

Disclaimer

This information is for educational purposes and does not replace professional medical advice. Always consult a healthcare provider for diagnosis, treatment recommendations, and personalized dosing. Do not self-medicate. Iverjohn is a prescription medication and should be used only under medical supervision.

Reviews

“After a confirmed diagnosis of strongyloidiasis, Iverjohn cleared my infection with just one dose. Minimal side effects and rapid symptom relief.” – Maria T., 42
“Used in our clinic for onchocerciasis control, Iverjohn has been reliable and well-tolerated in mass administration programs.” – Dr. Alade, Infectious Disease Specialist
“Effective, but requires careful patient screening. Not for everyone, but invaluable when indicated.” – Clinical Pharmacist, Endemic Region